Risks of Organ Preservation in Rectal Cancer: Data From Two International Registries on Rectal Cancer

Patients with LR appear to have a higher risk for subsequent DM development than patients with nPCR managed by TME at restaging irrespective of final pathology. Leaving the primary undetectable tumor in situ until development of LR may result in worse oncologic outcomes.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2024-10-28
DOI
https://doi.org/10.1200/jco.24.00405
Citations
26
Primary Topic
Colorectal Cancer Surgical Treatments
Type
article
Field-Weighted Citation Impact
7.35

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Risks of Organ Preservation in Rectal Cancer: Data From Two International Registries on Rectal Cancer

André D’Hoore, Alberto Parajó Calvo, Marion Arnold, Andrew G. Renehan et al.
26 citations
Journal of Clinical Oncology
Colorectal Cancer Surgical Treatments
7.35
article

Risks of Organ Preservation in Rectal Cancer: Data From Two International Registries on Rectal Cancer

André D’Hoore, Alberto Parajó Calvo, Marion Arnold, Andrew G. Renehan, Miquel Kraft, Claudio Coco, Chris Cunningham, Jean‐Pierre Gérard, Inês Santiago, Giuditta Chiloiro, Robert D. Madoff, Mamoon Solkar, Rafael Vaz Pandini, Arthur Sun Myint, Natália Mariana Felício, Rodrigo Oliva Perez, Katharina Leitner, Didac Ribé Serrat, Koen Peeters, C. Polanco Sánchez, Shyamji Rawat, Guilherme Pagin São Julião, Rocío Santos Rancaño, Jarno Melenhorst, Sebastiano Biondo, Francisco Blanco‐Antona, Carlos Álvarez Laso, Fernando Sánchez Loria, Stijn H. J. Ketelaers, Hester E. Haak, Barbara M. Geubels, Amjad C. Parvaiz, Mónica Reig Pérez, Per J. Nilsson, Cornelis J.�H. van de Velde, Bruna Borba Vailati, Laura M. Fernández, Carlos Cerdán Santacruz, Jesús Pedro Paredes Cotoré, Peirong Ding, Jiehai Yu, Blas Flor‐Lorente, Alberto Ignacio Herrando, Oktar Asoğlu, Noelia Ibáñez, Lars Henrik Jensen, José Azevedo, Zahirul Huq, Shahrzad Kordnejad, David M. Richards, José Enrique Sierra Grañón, Alexander Pennings, Karen Telford, Carlos Carvalho, Natalia Uribe Quintana, Isadora Rosa, Albert Wolthuis, Sofieke Temmink, Joaquim Gama‐Rodrigues, Anders Jakobsen, Lee Malcomson, Ana Benítez Riesco, Marta Jiménez Toscano, RS Kushwaha, Nieves Jaén Sánchez, Amir Keshvari, André Caiado, Krzysztof Bujko, Petra A. Custers, Elma Meershoek, Handan Tokmak, Angelita Habr‐Gama, R Coll, Óscar Cano-Valderrama, Mahdi Aghili, Uzair Ali Khan, J. Mateo, Olga Maseda Díaz, Sarah V. Ward, Ana Gálvez Saldaña, Roland Chautems, F Jacquinot, Jesús Cifuentes Tébar, K.H. Siddiqui, Paula Dujovne, H.J.T. Rutten, Sthela M. Murad‐Regadas, Elena Yagüe Martín, Nuno Figueiredo, Katja Fechner, Eloy Espín, Wolfgang B. Gaertner, Geerard L. Beets, M K Nouritaromlou, Anna Martling, Carlos Vaccaro, María del Coral de la Vega Olías, Daniel Huerga Álvarez, Klaus E. Matzel, Gustavo Rossi, Zhen Zhang, Jing Tang, Goffredo Paolo, Mauricio García Alonso, Wilson Manuel Sánchez Bautista, Derek A. Jones, Claudia Mazzarisi, Gabriel Dimofte, M. Sánchez, A V Calpe Climent, Jordan Hill, Ignasi Camps, E Gregory, Marta Cuadrado, S. Duff, Ignacio Aguirre Allende, Guillermo Ais, Isidora Salazar, Lameris Wytze, Eloy Espin Basan
article en
26 citations

Abstract

Patients with LR appear to have a higher risk for subsequent DM development than patients with nPCR managed by TME at restaging irrespective of final pathology. Leaving the primary undetectable tumor in situ until development of LR may result in worse oncologic outcomes.

Journal of Clinical OncologyVol. 43(14)
Champalimaud Foundation (PT), Universitat Autònoma de Barcelona (ES), National Health Service (GB), Leiden University Medical Center (NL), Karolinska Institutet (SE), University of Manchester (GB), The Netherlands Cancer Institute (NL), Hospital Clínico San Carlos (ES), Maastricht University (NL), Hospital Alemão Oswaldo Cruz (BR), Beneficência Portuguesa de São Paulo (BR), Leitat Technological Center (ES), Hospital Universitario de La Princesa (ES), The Christie NHS Foundation Trust (GB), NIHR Manchester Biomedical Research Centre (GB)
European Society of Surgical Oncology, Fundação Champalimaud, Manchester Biomedical Research Centre
Openalex Percentile: Top 2%
Colorectal Cancer Surgical Treatments
7.35
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.